Navigation Links
Emageon Receives Escrowed Funds and Terminates Merger Agreement
Date:2/13/2009

BIRMINGHAM, Ala., Feb. 13 /PRNewswire-FirstCall/ -- Emageon Inc. (Nasdaq: EMAG), a leader in enterprise medical information technology systems for hospitals and health care networks, announced today that it has received the $9 million that had been placed in escrow with The Bank of New York Mellon by Health Systems Solutions, Inc. (OTC Bulletin Board: HSSO) in connection with the parties' merger transaction. The escrowed funds became payable to Emageon when the merger was not consummated before the close of business on February 11, 2009.

Emageon also announced that it has terminated its amended merger agreement with Health Systems due to Health Systems' failure to receive all necessary financing on or before the designated closing date of February 11, 2009. Emageon continues to evaluate its options in response to these developments.

About Emageon

Emageon provides information technology systems for hospitals, healthcare networks and imaging facilities. Its enterprise family of solutions includes RadSuite(TM), HeartSuite(TM) and other specialty suites. All Emageon solutions are built on a unified Enterprise Content Management system offering advanced visualization and infrastructure tools for the clinical analysis and management of digital medical images, reports and associated clinical content. Emageon's standards-based solutions are designed to help customers enhance patient care, automate workflow, lower costs, improve productivity and provide better service to physicians. For more information, please visit www.emageon.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release regard matters that are not historical facts and are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding expectations as to the completion of the merger and other transactions contemplated by the merger agreement, Emageon's intentions or plans to enforce its rights under the merger agreement and the outcome of the litigation referred to in this release. These statements are often identified by the use of forward-looking words such as "believe," "expect," "potential," "continue," "may," "will," "should," "could," "would," "intend," "plan," "estimate," "anticipate" and comparable words or the negative version of these and other words. Because such forward-looking statements contain risks and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement and the possibility that Emageon could be required to pay a $3.0 million termination fee in connection therewith; the outcome of any legal proceedings that have been or may be instituted against Emageon and others related to the merger agreement; the failure to satisfy any conditions to the completion of the merger; the failure to obtain the necessary financing set forth in the debenture purchase agreement with SIBL to be received in connection with the merger; risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger; risks regarding a loss of or decrease in purchases by Emageon's major customers as a result of the merger; the ability to recognize the benefits of the merger; and the amount of the costs, fees, expenses and charges related to the merger and the actual terms of the financing that will be obtained for the merger. The business of Emageon is also subject to a number of risks generally such as: competition from larger competitors; risks associated with a history of operating losses; reliance on continuing relationships with large customers; the risk of significant product errors or product failures; reliance on reseller arrangements for important components of its solution; the risk of not responding effectively to changes in its industry; customers' reliance on third party reimbursements; risks regarding the potential impact on its business of FDA regulations and other applicable health care regulations; and other risks that are set forth in the "Risk Factors," "Legal Proceedings" and "Management Discussion and Analysis of Results of Operations and Financial Condition" sections of, and elsewhere in, the filings that Emageon makes with the Securities and Exchange Commission. Many of the factors that will determine the outcome of the subject matter of this press release are beyond Emageon's ability to control or predict. Emageon undertakes no obligation to release publicly the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.


'/>"/>
SOURCE Emageon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Emageon Reports Third Quarter 2007 Financial Results
2. Emageon Names Chris E. Perkins as Chief Operating Officer
3. Emageon to Present at the 26th Annual JPMorgan Healthcare Conference
4. Foundation Radiology Group Formalizes Strategic Partnership with Emageon to Provide Advanced Imaging Software to Facilitate Industry-Leading Turnaround and Patient Care Response Times
5. Emageon Inc. to Host Fourth Quarter 2007 Financial Results Conference Call February 21, 2008
6. Emageon Reports Fourth Quarter and 2007 Financial Results
7. Emageon to Present at Raymond James 29th Annual Institutional Investors Conference
8. Emageon Receives Best in KLAS Cardiology PACS Award
9. Emageon Inc. to Host First Quarter 2008 Financial Results Conference Call May 12, 2008
10. Emageon to Present at the Jefferies 2nd Annual Healthcare Conference
11. Emageon Selects Jefferies & Company and SunTrust Robinson Humphrey as Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: